Literature DB >> 24153173

Effectiveness and safety of recombinant human bone morphogenetic protein-2 versus local bone graft in primary lumbar interbody fusions.

Cameron Louis Adams1, Kathryn Ogden, Iain Kilpatrick Robertson, Stephen Broadhurst, David Edis.   

Abstract

STUDY
DESIGN: Retrospective cohort study.
OBJECTIVE: To compare clinical outcomes, fusion rates, and rates of complications in posterior lumbar interbody fusions (PLIFs) and transforaminal lumbar interbody fusion procedures with either recombinant human bone morphogenetic protein-2 (rhBMP-2) and local bone graft (LBG) or LBG alone used as graft material. SUMMARY OF BACKGROUND DATA: rhBMP-2 is often used in PLIF and transforaminal lumbar interbody fusion procedures, but is associated with complications. Furthermore, recent evidence suggests that using LBG may be sufficient to induce fusion.
METHODS: All patients who underwent primary interbody fusions under a single surgeon were identified from the surgeon's records. In November 2008, the surgeon changed from routinely using LBG to using LBG and rhBMP-2 routinely, limiting selection bias. A retrospective review of prospectively collected data preoperatively and up to 12 months postoperatively was performed. Data collected included visual analogue scale, pain scores for back and leg, Oswestry Disability Index scores, Short-Form 36 (SF-36), standing lumbar radiographs, and clinical notes.
RESULTS: Seventy-seven patients met the study criteria and 70 consented to be part of the study. Fifty-one were treated with rhBMP-2 and 19 with LBG. At 12-month follow-up, no significant differences were seen in visual analogue scale score, Oswestry Disability Index score, or SF-36 scores. A total of 89.5% of the LBG group and 94.1% of the rhBMP-2 group went on to show radiographical evidence of fusion by 12-month follow-up (P = 0.61). The rhMBP-2 group had a higher complication rate (41.2% vs. 10.5%, incidence rate ratio = 3.91, P = 0.05).
CONCLUSION: In comparison we found no difference in clinical outcomes, comparable rates of fusion and a significant increase in complication rates with rhBMP-2. Using rhBMP-2 may unnecessarily increase the risk of complication in routine PLIF and transforaminal lumbar interbody fusion procedures. LEVEL OF EVIDENCE: 3.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24153173     DOI: 10.1097/BRS.0000000000000089

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  9 in total

1.  Bone substitutes and expanders in Spine Surgery: A review of their fusion efficacies.

Authors:  Abhijeet Kadam; Paul W Millhouse; Christopher K Kepler; Kris E Radcliff; Michael G Fehlings; Michael E Janssen; Rick C Sasso; James J Benedict; Alexander R Vaccaro
Journal:  Int J Spine Surg       Date:  2016-09-22

2.  Lumbar interbody fusion with utilization of recombinant human bone morphogenetic protein: a retrospective real-life study about 277 patients.

Authors:  Stéphane Litrico; Tristan Langlais; Florent Pennes; Antoine Gennari; Philippe Paquis
Journal:  Neurosurg Rev       Date:  2017-03-10       Impact factor: 3.042

Review 3.  BMP-2-induced bone formation and neural inflammation.

Authors:  Vi Nguyen; Carolyn A Meyers; Noah Yan; Shailesh Agarwal; Benjamin Levi; Aaron W James
Journal:  J Orthop       Date:  2017-03-20

Review 4.  Growth factors in orthopaedic surgery: demineralized bone matrix versus recombinant bone morphogenetic proteins.

Authors:  Maurice Hinsenkamp; Jean-Francois Collard
Journal:  Int Orthop       Date:  2014-10-22       Impact factor: 3.075

5.  Evaluation of an increased strut porosity silicate-substituted calcium phosphate, SiCaP EP, as a synthetic bone graft substitute in spinal fusion surgery: a prospective, open-label study.

Authors:  Ciaran Bolger; Drew Jones; Steven Czop
Journal:  Eur Spine J       Date:  2019-03-05       Impact factor: 3.134

6.  mTOR inhibition and BMP signaling act synergistically to reduce muscle fibrosis and improve myofiber regeneration.

Authors:  Shailesh Agarwal; David Cholok; Shawn Loder; John Li; Christopher Breuler; Michael T Chung; Hsiao Hsin Sung; Kavitha Ranganathan; Joe Habbouche; James Drake; Joshua Peterson; Caitlin Priest; Shuli Li; Yuji Mishina; Benjamin Levi
Journal:  JCI Insight       Date:  2016-12-08

7.  Small molecule-mediated tribbles homolog 3 promotes bone formation induced by bone morphogenetic protein-2.

Authors:  Jiabing Fan; Joan Pi-Anfruns; Mian Guo; Dan C S Im; Zhong-Kai Cui; Soyon Kim; Benjamin M Wu; Tara L Aghaloo; Min Lee
Journal:  Sci Rep       Date:  2017-08-08       Impact factor: 4.379

8.  A comparison of radiographic and clinical outcomes of anterior lumbar interbody fusion performed with either a cellular bone allograft containing multipotent adult progenitor cells or recombinant human bone morphogenetic protein-2.

Authors:  Daniel Dongwhan Lee; John Yongmin Kim
Journal:  J Orthop Surg Res       Date:  2017-08-25       Impact factor: 2.359

Review 9.  Quality of Life in Patients Undergoing Spine Surgery: Systematic Review and Meta-Analysis.

Authors:  Nikhil R Nayak; James H Stephen; Matthew A Piazza; Adetokunbo A Obayemi; Sherman C Stein; Neil R Malhotra
Journal:  Global Spine J       Date:  2018-07-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.